title: Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U).
abstract: OBJECTIVE
  The aim of this study was to assess the prognostic factors of peripheral T-cell lymphoma, unspecified (PTCL-U).
  
  
  METHODS
  We retrospectively analyzed 30 cases fulfilling the criteria of PTCL-U defined by the World Health Organization classification. The patients were treated with 6-8 cycles of a CHOP or THP (pirarubicin)-COP regimen.
  
  
  RESULTS
  A high serum sIL-2R level (> or =2,000 U/ml) at onset was associated with a low complete remission rate. Patients with high sIL-2R had significantly lower survival rates (5 year, 15.1%) than those with low sIL-2R (<2,000 U/ml) (100%) (P < 0.005). Factors associated with worse overall survival in a univariate analysis were high sIL-2R (P < 0.005), high age (>60 years) (P < 0.05), poor performance status (P < 0.01) and poor international prognostic index (P < 0.05). No correlation was observed between sIL-2R and other markers. Multivariate analysis showed that only sIL-2R was a prognostic factor for overall survival (P < 0.01).
  
  
  CONCLUSIONS
  The results suggest that a high serum sIL-2R level predicts a poor prognosis in PTCL-U.
authors.affiliation: First Department of Internal Medicine, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.
authors.forename: Jun-ichi
authors.initials: J
authors.lastname: Kitagawa
authors.forename: Takeshi
authors.initials: T
authors.lastname: Hara
authors.forename: Hisashi
authors.initials: H
authors.lastname: Tsurumi
authors.forename: Naoe
authors.initials: N
authors.lastname: Goto
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Kanemura
authors.forename: Takeshi
authors.initials: T
authors.lastname: Yoshikawa
authors.forename: Senji
authors.initials: S
authors.lastname: Kasahara
authors.forename: Toshiki
authors.initials: T
authors.lastname: Yamada
authors.forename: Michio
authors.initials: M
authors.lastname: Sawada
authors.forename: Takeshi
authors.initials: T
authors.lastname: Takahashi
authors.forename: Masahito
authors.initials: M
authors.lastname: Shimizu
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Takami
authors.forename: Hisataka
authors.initials: H
authors.lastname: Moriwaki
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor; D005260:Female; D006801:Humans; D016411:Lymphoma, T-Cell, Peripheral / Q000097:blood* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D015375:Receptors, Interleukin-2 / Q000097:blood*; D012074:Remission Induction; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D015375:Receptors, Interleukin-2